SBIR-STTR Award

Murine Monochromosomal Hybrid Panels
Award last edited on: 4/24/02

Sponsored Program
SBIR
Awarding Agency
NIH : NIDA
Total Award Amount
$84,981
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Young S Chang

Company Information

S C Genome Research

30091 Myfair Road
Farmington Hill, MI 48331
   (248) 661-2355
   yschang@earthlink.net
   N/A
Location: Single
Congr. District: 14
County: Oakland

Phase I

Contract Number: 7R43DA011148-02
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1996
Phase I Amount
$84,981
Next to humans, the mouse is the most important mammal used for genetic and biomedical studies. The study of the mouse genome has become an integral component of the Human Genome Project. Development of a high resolution genetic map of the mouse has progressed rapidly, but physical mapping, identification of genes, and sequencing of the mouse genome remain to be developed. Somatic cell genetic methods provide powerful techniques for those studies, yet they have rarely been applied for the study of the mouse genome. To this end, it is crucial to construct a panel of mouse monochromosomal hybrid cells which can be readily and efficiently available tot he scientific community. We propose to develop a panel of mouse monochromosomal hybrids to provide the exact resources needed. These hybrids can be constructed using microcell fusion techniques and can be easily and accurately characterized using the recently developed methods of fluorescence in situ hybridization (FISH), PCR-based gene marker analysis, and chromosome banding analysis. The monochromosomal hybrids products will provide a very valuable resource for: (a) developing a physical map of the mouse genome; (b) construction of chromosome specific libraries; (c) isolation of genes and DNA markers; and (d) ultimately developing mouse models for human diseases.Proposed commercial application:Wide distribution of the monochromosomal hybrid panel will permit rapid characterization of the mouse genome which in turn, will accelerate progression of the Human Genome Program. Therefore, this project is scientifically significant and commercially valuable.National Institute on Drug Abuse (NIDA)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----